Case number 1:23-cv-00401
Novartis Pharmaceuticals Corporation v. Nanjing Noratech Pharmaceutical Co., Limited > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 24, 2025 | 211 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,101,659; 11,058,667. (Attachments: # 1 Consent Judgment (redacted))(nms) (Entered: 06/24/2025) (0) |
| Jun 23, 2025 | 209 | REDACTED VERSION of 204 Proposed Consent Judgment by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 06/23/2025) (4) |
| Jun 23, 2025 | 210 | REDACTED VERSION of 208 Consent Judgment, by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 06/23/2025) (4) |
| Jun 17, 2025 | 208 | [SEALED] CONSENT JUDGMENT between Novartis Pharmaceuticals Corporation and Gerbera Therapeutics Inc. and Nanjing Noratech Pharmaceutical Co.. Signed by Judge Richard G. Andrews on 6/17/2025.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 06/17/2025) (0) |
| Jun 16, 2025 | 206 | REDACTED VERSION of 203 Letter by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 06/16/2025) (2) |
| Jun 16, 2025 | 207 | STIPULATION and [Proposed] Order to Extend Time to File Redacted Version, by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) Modified on 6/16/2025 (nms). (Entered: 06/16/2025) (2) |
| Jun 10, 2025 | 205 | REDACTED VERSION of 201 Letter by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 06/10/2025) (2) |
| Jun 9, 2025 | 203 | [SEALED] Joint letter to The Honorable Richard G. Andrews, from the Parties, regarding status. (O'Brien, Daniel) Modified on 6/10/2025 (nms). (Entered: 06/09/2025) (0) |
| Jun 9, 2025 | 204 | [SEALED] Proposed Consent Judgment and Order of Injunction, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(O'Brien, Daniel) Modified on 6/9/2025 (nms). (Entered: 06/09/2025) (0) |
| Jun 3, 2025 | 200 | MANDATE of USCA as to 31 Notice of Appeal (Federal Circuit), filed by Novartis Pharmaceuticals Corporation. USCA Decision: The district court's judgment is vacated and the cases remanded to the district court for further proceedings. (Attachments: # 1 Order/Judgment)(nms) (Entered: 06/03/2025) (0) |
| Jun 3, 2025 | 201 | [SEALED] Joint Letter to The Honorable Richard G. Andrews, from the Parties, regarding Status. (O'Brien, Daniel) (Entered: 06/03/2025) (0) |
| Jun 3, 2025 | 202 | REDACTED VERSION of 199 Letter by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 06/03/2025) (2) |
| May 27, 2025 | 198 | ORDER on Petition for Panel Rehearing and Rehearing En Banc of USCA as to 31 Notice of Appeal (Federal Circuit), filed by Novartis Pharmaceuticals Corporation. Decision of USCA: The petition for panel rehearing is denied. The petition for rehearing en banc is denied. (nms) (Entered: 05/27/2025) (2) |
| May 27, 2025 | 199 | [SEALED] Joint letter to The Honorable Richard G. Andrews, from the Parties, regarding status. (O'Brien, Daniel) Modified on 5/28/2025 (nms). (Entered: 05/27/2025) (0) |
| May 22, 2025 | 197 | REDACTED VERSION of 193 Letter by Novartis Pharmaceuticals Corporation. (O'Brien, Daniel) (Entered: 05/22/2025) (2) |
| May 20, 2025 | 196 | NOTICE of Appearance by Daniel A. O'Brien on behalf of Novartis Pharmaceuticals Corporation (O'Brien, Daniel) (Entered: 05/20/2025) (2) |
| May 16, 2025 | 194 | REDACTED VERSION of 189 Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 5/19/2025 (nms). (Entered: 05/16/2025) (2) |
| May 16, 2025 | 195 | REDACTED VERSION of 191 Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 5/19/2025 (nms). (Entered: 05/16/2025) (2) |
| May 15, 2025 | 193 | [SEALED] Joint letter to The Honorable Richard G. Andrews, from the Parties, regarding status. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 5/15/2025 (nms). (Entered: 05/15/2025) (0) |
| May 12, 2025 | 192 | STIPULATION and Proposed Order to Extend Time to submit a public redacted version of Joint Letter (D.I. 1861 in 20-md-2930; D.I. 469 in 22-1395; and D.I. 191 in 23-401) to May 16, 2025 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 5/13/2025 (nms). (Entered: 05/12/2025) (3) |
| May 5, 2025 | 191 | [SEALED] Joint letter to The Honorable Richard G. Andrews, from the Parties, regarding status. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 5/5/2025 (nms). (Entered: 05/05/2025) (0) |
| May 2, 2025 | 190 | STIPULATION and Proposed Order to Extend Time to submit a public redacted version of the joint letter to The Honorable Richard G. Andrews from the Parties Regarding Case Status to May 16, 2025 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/2/2025 (nms). (Entered: 05/02/2025) (3) |
| Apr 25, 2025 | 189 | [SEALED] Joint Letter to The Honorable Richard G. Andrews, from The Parties, regarding status. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 4/25/2025 (nms). (Entered: 04/25/2025) (0) |
| Apr 4, 2025 | 188 | Response to Novartis's Notice of Supplemental Authority (D.I. 187 ), by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 4/4/2025 (nms). (Entered: 04/04/2025) (2) |
| Apr 1, 2025 | 187 | NOTICE of Supplemental Authority by Novartis Pharmaceuticals Corporation (Attachments: # 1 Exhibit A)(Silver, Daniel) (Entered: 04/01/2025) (0) |
| Mar 11, 2025 | 186 | ORDER of USCA as to 31 Notice of Appeal (Federal Circuit), filed by Novartis Pharmaceuticals Corporation. Decision of USCA: The district courts judgment is vacated and the cases remanded to the district court for further proceedings. The district courts judgment is stayed until issuance of mandate in Appeal Nos. 2023-2317, 2023-2319. Any pending motion otherwise is denied. Each party shall bear its own costs. (nms) (Entered: 03/11/2025) (2) |
| Feb 24, 2025 | 185 | REDACTED VERSION of 179 POST-Trial Brief, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 2/25/2025 (nms). (Entered: 02/24/2025) (18) |
| Feb 20, 2025 | 182 | Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, Esq., enclosing USB drives containing post-trial documents. (Gattuso, Dominick) Modified on 2/20/2025 (nms). (Entered: 02/20/2025) (1) |
| Feb 20, 2025 | 183 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding electronic versions of post-trial documents. (Silver, Daniel) Modified on 2/20/2025 (nms). (Entered: 02/20/2025) (1) |
| Feb 20, 2025 | 184 | SO ORDERED Granting (D.I. 1796 in 20-md-2930-RGA; D.I. 181 in 23-cv-401-RGA) Stipulation and Proposed Order Regarding Admission of Third-Party Confidential Trial Exhibits. Signed by Judge Richard G. Andrews on 2/20/2025. Associated Cases: 1:20-md-02930-RGA, 1:23-cv-00401-RGA(nms) (Entered: 02/20/2025) (15) |
| Feb 19, 2025 | 181 | STIPULATION and [Proposed] Order Regarding Admission of Third-Party Confidential Trial Exhibits by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Silver, Daniel) (Entered: 02/19/2025) (0) |
| Feb 14, 2025 | 177 | REDACTED VERSION of 170 POST-Trial Brief, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 2/14/2025 (nms). (Entered: 02/14/2025) (30) |
| Feb 14, 2025 | 178 | REDACTED VERSION of 171 Proposed Findings of Fact, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 2/14/2025 (nms). (Entered: 02/14/2025) (27) |
| Feb 14, 2025 | 179 | [SEALED] Post-Trial Reply Brief on Infringement of the '667 Patent, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 2/14/2025 (nms). (Entered: 02/14/2025) (0) |
| Feb 14, 2025 | 180 | POST-TRIAL Reply Brief Regarding the Invalidity of the '667 Patent, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 2/18/2025 (nms). (Entered: 02/14/2025) (21) |
| Feb 12, 2025 | 174 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., enclosing electronic versions of post-trial documents. (Silver, Daniel) Modified on 2/13/2025 (nms). (Entered: 02/12/2025) (1) |
| Feb 12, 2025 | 175 | REDACTED VERSION of 173 Notice of Lodging of Defendants' Trial Demonstratives, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit 5, # 2 Exhibit 6)(Gattuso, Dominick) Modified on 2/12/2025 (nms). (Entered: 02/12/2025) (0) |
| Feb 12, 2025 | 176 | Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, Esq, enclosing USB drives containing Post-Trial Documents . (Gattuso, Dominick) Modified on 2/12/2025 (nms). (Entered: 02/12/2025) (1) |
| Feb 11, 2025 | 172 | NOTICE of Lodging of Defendants' Trial Demonstratives by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4)(Gattuso, Dominick) (Entered: 02/11/2025) (0) |
| Feb 11, 2025 | 173 | [SEALED] NOTICE of Lodging of Defendants' Trial Demonstratives by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited (Attachments: # 1 Exhibit 5, # 2 Exhibit 6, # 3 Certificate of Service)(Gattuso, Dominick) (Entered: 02/11/2025) (0) |
| Feb 7, 2025 | 168 | POST-TRIAL Answering on Validity of the '667 Patent, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 2/7/2025 (nms). (Entered: 02/07/2025) (30) |
| Feb 7, 2025 | 169 | Proposed Findings of Fact by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 02/07/2025) (30) |
| Feb 7, 2025 | 170 | [SEALED] POST-TRIAL Answering Brief Regarding Non-Infringement of the 667 Patent, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Certificate of Service)(Gattuso, Dominick) Modified on 2/10/2025 (nms). (Entered: 02/07/2025) (0) |
| Feb 7, 2025 | 171 | [SEALED] Proposed Findings of Fact by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Certificate of Service)(Gattuso, Dominick) (Entered: 02/07/2025) (0) |
| Jan 30, 2025 | 167 | ORDER of USCA as to 31 Notice of Appeal (Federal Circuit), filed by Novartis Pharmaceuticals Corporation. Decision of USCA: Nanjing Noratech Pharmaceutical Co., Ltd. submits a motion to dismiss. Upon consideration thereof. IT IS ORDERED THAT: Any response to the motion to dismiss is due no later than February 6, 2025. (nms) (Entered: 01/30/2025) (2) |
| Jan 29, 2025 | 166 | SO ORDERED Granting Stipulation and Order Regarding Submission of Admitted Exhibits Cited in Post-Trial Briefing (D.I. 165 in 23-cv-401-RGA; D.I. 457 in 22-cv-1395-RGA; D.I. 1754 in 20-md-2930-RGA). Signed by Judge Richard G. Andrews on 1/29/2025. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 01/29/2025) (4) |
| Jan 28, 2025 | 164 | REDACTED VERSION of 155 Proposed Findings of Fact, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 1/28/2025 (nms). (Entered: 01/28/2025) (30) |
| Jan 28, 2025 | 165 | STIPULATION and Order Regarding Submission of Admitted Exhibits Cited in Post-Trial Briefing by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 01/28/2025) (4) |
| Jan 22, 2025 | 162 | STIPULATION and Order Regarding Post-Trial Briefing, by MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., MSN Laboratories Private Limited. (Weinblatt, Richard) Modified on 1/22/2025 (nms). (Entered: 01/22/2025) (4) |
| Jan 22, 2025 | 163 | SO ORDERED Granting Stipulation and Order Regarding Post-Trial Briefing (D.I. 162 in 23-cv-401-RGA; D.I. 455 in 22-cv-1395-RGA; D.I. 1749 in 20-md-2930-RGA). Signed by Judge Richard G. Andrews on 1/22/2025. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 01/22/2025) (4) |
| Jan 21, 2025 | 160 | Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, Esq., enclosing USB drives containing post-trial documents. (Gattuso, Dominick) Modified on 1/21/2025 (nms). (Entered: 01/21/2025) (1) |
| Jan 21, 2025 | 161 | MOTION to Modify the Post-Trial Briefing Schedule - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Weinblatt, Richard) Modified on 1/21/2025 (nms). (Entered: 01/21/2025) (0) |
| Jan 17, 2025 | 159 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., enclosing electronic versions of post-trial documents. (Silver, Daniel) Modified on 1/17/2025 (nms). (Entered: 01/17/2025) (1) |
| Jan 16, 2025 | 158 | STIPULATION TO EXTEND TIME for Noratech to submit hyperlinked versions of their Post-Trial Opening Brief and Findings of Fact regarding the 667 patent to January 21, 2025 - filed by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 01/16/2025) (2) |
| Jan 10, 2025 | 154 | POST-TRIAL Opening Brief on Infringement of the '667 Patent, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 1/11/2025 (nms). (Entered: 01/10/2025) (26) |
| Jan 10, 2025 | 155 | [SEALED] Proposed Findings of Fact by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 01/10/2025) (0) |
| Jan 10, 2025 | 156 | POST-TRIAL Opening Brief Regarding the Invalidity of the 667 Patent, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 1/11/2025 (nms). (Entered: 01/10/2025) (30) |
| Jan 10, 2025 | 157 | Proposed Findings of Fact by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 01/10/2025) (30) |
| Jan 9, 2025 | 153 | ORDER of USCA as to 31 Notice of Appeal (Federal Circuit), filed by Novartis Pharmaceuticals Corporation. Decision of USCA: Noratech is directed to respond to the motion no later than January 14, 2025. Any reply in support of the motion is due no later than January 15, 2025. The district courts August 16, 2023 judgment of invalidity of the '659 patent is stayed pending consideration of this motion. Noratech is directed to inform the court at least 48 business hours before Noratech anticipates commencing commercial marketing or sales of its generic version of Entresto. (nms) (Entered: 01/09/2025) (2) |
| Dec 31, 2024 | 148 | Official Transcript of Bench Trial held on 12/09/24 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/21/2025. Redacted Transcript Deadline set for 1/31/2025. Release of Transcript Restriction set for 3/31/2025. (Triozzi, Heather) (Entered: 12/31/2024) (341) |
| Dec 31, 2024 | 149 | Official Transcript of Bench Trial held on 12/10/24 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/21/2025. Redacted Transcript Deadline set for 1/31/2025. Release of Transcript Restriction set for 3/31/2025. (Triozzi, Heather) (Entered: 12/31/2024) (311) |
| Dec 31, 2024 | 150 | Official Transcript of Bench Trial held on 12/11/24 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/21/2025. Redacted Transcript Deadline set for 1/31/2025. Release of Transcript Restriction set for 3/31/2025. (Triozzi, Heather) (Entered: 12/31/2024) (206) |
| Dec 31, 2024 | 151 | Official Transcript of Bench Trial held on 12/12/24 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/21/2025. Redacted Transcript Deadline set for 1/31/2025. Release of Transcript Restriction set for 3/31/2025. (Triozzi, Heather) (Entered: 12/31/2024) (188) |
| Dec 31, 2024 | 152 | Official Transcript of Bench Trial held on 12/13/24 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/21/2025. Redacted Transcript Deadline set for 1/31/2025. Release of Transcript Restriction set for 3/31/2025. (Triozzi, Heather) (Entered: 12/31/2024) (131) |
| Dec 20, 2024 | 147 | Admitted Trial Exhibits for Bench Trial held 12/10/2024 - 12/13/2024, Regarding U.S. Patent Nos. 11,058,667 and 11,096,918, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/20/2024 (nms). (Entered: 12/20/2024) (21) |
| Dec 18, 2024 | 143 | STIPULATION and Order Regarding Post-Trial Briefing by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 12/18/2024) (6) |
| Dec 18, 2024 | 144 | SO ORDERED Granting (D.I. 1694 in 20-md-2930-RGA; D.I. 143 in 23-cv-401-RGA; D.I. 437 in 22-cv-1395-RGA) Stipulation and Order Regarding Post-Trial Briefing. Signed by Judge Richard G. Andrews on 12/18/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 12/18/2024) (6) |
| Dec 18, 2024 | 145 | REDACTED VERSION of 120 Proposed Pretrial Order, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/18/2024 (nms). (Entered: 12/18/2024) (30) |
| Dec 18, 2024 | 146 | REDACTED VERSION of 139 Amended Exhibits, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/19/2024 (nms). (Entered: 12/18/2024) (24) |
| Dec 13, 2024 | 142 | STIPULATION and Proposed Order to Extend Time to submit a redacted public version of Amended Exhibits 6-M and 8 to Joint Pretrial Order Regarding U.S. Patent Nos. 11,096,918 and 11,058,667 (D.I. 1690) to December 18, 2024 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/16/2024 (nms). (Entered: 12/13/2024) (3) |
| Dec 10, 2024 | 140 | MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Text of Proposed Order)(Silver, Daniel) (Entered: 12/10/2024) (0) |
| Dec 10, 2024 | 141 | ORDER Granting Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices (D.I. 434 in 22-cv-1395-RGA; D.I. 1691 in 20-md-2930-RGA; D.I. 140 in 23-cv-401-RGA). Signed by Judge Richard G. Andrews on 12/10/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 12/10/2024) (2) |
| Dec 8, 2024 | 137 | MOTION for Pro Hac Vice Appearance of Attorney Susanne L. Flanders - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification)(Joyce, Alexandra) (Entered: 12/08/2024) (0) |
| Dec 8, 2024 | 138 | Pro Hac Vice Fee - Credit Card Payment received for Susanne L. Flanders. ( re 137 MOTION for Pro Hac Vice Appearance of Attorney Susanne L. Flanders )( Payment of $ 50, receipt number ADEDC-4564883).(Joyce, Alexandra) (Entered: 12/08/2024) (0) |
| Dec 8, 2024 | 139 | [SEALED] Amended Exhibits 6-M and 8 to Pretrial Order (D.I. 120 ), by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 6-M, # 2 Exhibit 8, # 3 Certificate of Service)(Joyce, Alexandra) Modified on 12/9/2024 (nms). (Entered: 12/08/2024) (0) |
| Dec 5, 2024 | 135 | ORDER: The Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices (D.I. 1678 in 20-md-2930-RGA; D.I. 133 in 23-cv-401-RGA; D.I. 421 in 22-cv-1395-RGA) is GRANTED. Signed by Judge Richard G. Andrews on 12/5/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 12/05/2024) (2) |
| Dec 5, 2024 | 136 | ORDER: The Motion for Exemption from the District of Delaware's May 17, 2024 Standing Order on Personal Devices (D.I. 131 in 23-cv-401-RGA; D.I. 419 in 22-cv-1395-RGA; D.I. 1676 in 20-md-2930-RGA) is GRANTED as modified. Signed by Judge Richard G. Andrews on 12/5/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 12/05/2024) (2) |
| Dec 4, 2024 | 130 | ORDER AFTER PRETRIAL CONFERENCE: The Proposed Pretrial Order (D.I. 1641 ) is ADOPTED, as modified by any discussion at the pretrial conference.The motion in limine to preclude MSN's written description and enablement arguments (D.I. 1639 ) is DENIED. The motion in limine to preclude reference to evidence and "court comments" from the Hetero case (D.I. 1637 ) is GRANTED. The motion in limine to preclude Dr. Spinale from "referencing his undocumented treatment practices" (D.I. 1638 ) is DENIED. (see Order for further details). Signed by Judge Richard G. Andrews on 12/4/2024. (aas) (Entered: 12/04/2024) (3) |
| Dec 4, 2024 | 131 | MOTION for Exemption from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Proposed Order)(Gattuso, Dominick) Modified on 12/4/2024 (nms). (Entered: 12/04/2024) (0) |
| Dec 4, 2024 | 132 | MOTION for Pro Hac Vice Appearance of Attorney Erin Belfield - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification of Erin Belfield)(Joyce, Alexandra) (Entered: 12/04/2024) (0) |
| Dec 4, 2024 | 133 | MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Text of Proposed Order)(Silver, Daniel) (Entered: 12/04/2024) (0) |
| Dec 4, 2024 | 134 | Pro Hac Vice Fee - Credit Card Payment received for Erin Belfield. ( re 132 MOTION for Pro Hac Vice Appearance of Attorney Erin Belfield )( Payment of $ 50, receipt number ADEDC-4562451).(Silver, Daniel) (Entered: 12/04/2024) (0) |
| Dec 3, 2024 | 128 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding curriculum vitae for Novartis experts. (Silver, Daniel) Modified on 12/3/2024 (nms). (Entered: 12/03/2024) (1) |
| Dec 3, 2024 | 129 | Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, Esq., regarding curriculum vitae of Defendants Gerbera Therapeutics, Inc.'s and Nanjing Noratech Pharmaceutical Co., Ltd.'s experts. (Gattuso, Dominick) Modified on 12/3/2024 (nms). (Entered: 12/03/2024) (1) |
| Dec 2, 2024 | 127 | Official Transcript of Pretrial Conference held on 11/22/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 12/23/2024. Redacted Transcript Deadline set for 1/2/2025. Release of Transcript Restriction set for 3/3/2025. (Triozzi, Heather) (Entered: 12/02/2024) (100) |
| Nov 26, 2024 | 126 | Pro Hac Vice Fee - Credit Card Payment received for Avery Hitchcock. ( re 125 MOTION for Pro Hac Vice Appearance of Attorney Avery Hitchcock )( Payment of $ 50, receipt number ADEDC-4557361).(Gattuso, Dominick) (Entered: 11/26/2024) (0) |
| Nov 25, 2024 | 125 | MOTION for Pro Hac Vice Appearance of Attorney Avery Hitchcock - filed by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 11/25/2024) (4) |
| Nov 21, 2024 | 121 | MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order)(Silver, Daniel) (Entered: 11/21/2024) (0) |
| Nov 21, 2024 | 122 | STIPULATION TO EXTEND TIME to file a redacted version of the Pretrial Order to December 18, 2024 - filed by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 11/21/2024) (3) |
| Nov 21, 2024 | 123 | ORDER: The Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices (D.I. 398 in 22-cv-1395-RGA; D.I. 121 in 23-cv-401-RGA; D.I. 1649 in 20-md-2930-RGA) is GRANTED. Signed by Judge Richard G. Andrews on 11/21/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 11/21/2024) (2) |
| Nov 21, 2024 | 124 | REDACTED VERSION of 119 MOTION in Limine No. 2: To Preclude Dr. Spinale from Referencing His Undocumented Treatment Practices, by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/21/2024 (nms). (Entered: 11/21/2024) (30) |
| Nov 18, 2024 | 119 | [SEALED] MOTION in Limine No. 2: To Preclude Dr. Spinale from Referencing His Undocumented Treatment Practices - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Defendants' Exhibits, # 2 Plaintiff's Exhibits, # 3 Certificate of Service)(Gattuso, Dominick) Modified on 11/18/2024 (nms). (Entered: 11/18/2024) (0) |
| Nov 18, 2024 | 120 | [SEALED] Proposed Pretrial Order by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1A, # 2 Exhibit 1A-N, # 3 Exhibit 1B, # 4 Exhibit 2A, # 5 Exhibit 2A-M, # 6 Exhibit 2A-N, # 7 Exhibit 2B, # 8 Exhibit 3A, # 9 Exhibit 3A-N, # 10 Exhibit 3B, # 11 Exhibit 4A, # 12 Exhibit 4B, # 13 Exhibit 5A, # 14 Exhibit 5B, # 15 Exhibit 6, # 16 Exhibit 6-M, # 17 Exhibit 6-N, # 18 Exhibit 7, # 19 Exhibit 7-M, # 20 Exhibit 7-N, # 21 Exhibit 8, # 22 Exhibit 9A, # 23 Exhibit 9B, # 24 Exhibit 10A, # 25 Exhibit 10B, # 26 Exhibit 11A, # 27 Exhibit 11B, # 28 Exhibit 12A, # 29 Exhibit 12B)(Silver, Daniel) (Entered: 11/18/2024) (0) |
| Nov 8, 2024 | 118 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc.'s Notice Pursuant to 35 U.S.C. § 282 filed by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 11/08/2024) (2) |
| Oct 31, 2024 | 116 | Joint Stipulation to Narrow Issues for Trial, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 10/31/2024 (nms). (Entered: 10/31/2024) (3) |
| Oct 31, 2024 | 117 | SO ORDERED Granting Joint Stipulation to Narrow Issues for Trial (D.I. 1611 in 20md2930-RGA; D.I. 116 in 23-cv-00401-RGA). Signed by Judge Richard G. Andrews on 10/31/2024. Associated Cases: 1:20-md-02930-RGA, 1:23-cv-00401-RGA(nms) (Entered: 10/31/2024) (3) |
| Oct 22, 2024 | 115 | NOTICE OF SERVICE of Supplemental Expert Report of Stuart D. Katz Regarding the Validity of U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 10/22/2024) (2) |
| Oct 8, 2024 | 114 | ORAL ORDER: The Scheduling Orders filed on July 6, 2023 (D.I. 1097 and 1098 in 20-md-2930-RGA; D.I. 85 in 22-cv-1395-RGA; D.I. 19 in 23-cv-401-RGA) are now AMENDED to reflect as follows regarding paragraph 10, subsection b: "Absent an order of the Court upon showing of good cause, each side is limited to one twenty-page opening brief, one twenty-page answering brief, and one ten-page reply brief for all its Daubert motions". Ordered by Judge Richard G. Andrews on 10/8/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 10/08/2024) (0) |
| Sep 19, 2024 | 113 | NOTICE to Take Deposition of Kiran Khush, M.D. on September 26, 2024 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/19/2024) (2) |
| Sep 17, 2024 | 112 | NOTICE to Take Deposition of Stuart D. Katz, M.D. on September 24, 2024 filed by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 09/17/2024) (2) |
| Sep 12, 2024 | 110 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts and Shannon K. Clark - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certifications for Melinda R. Roberts and Shannon K. Clark)(Silver, Daniel) (Entered: 09/12/2024) (0) |
| Sep 12, 2024 | 111 | Pro Hac Vice Fee - Credit Card Payment received for Melinda R. Roberts and Shannon K. Clark. ( re 110 MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts and Shannon K. Clark )( Payment of $ 100, receipt number ADEDC-4496773).(Silver, Daniel) (Entered: 09/12/2024) (0) |
| Sep 9, 2024 | 109 | ORDER Granting (D.I. 289 in 22-cv-1395-RGA; D.I. 108 in 23-cv-401-RGA; D.I. 1530 in 20-md-2930-RGA) Unopposed Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices. Signed by Judge Richard G. Andrews on 9/9/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 09/09/2024) (2) |
| Sep 6, 2024 | 108 | Unopposed Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order)(Silver, Daniel) Modified on 9/9/2024 (nms). (Entered: 09/06/2024) (0) |
| Aug 30, 2024 | 106 | NOTICE to Take Deposition of Aeri Park PH.D. on 09/04/2024 filed by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 08/30/2024) (2) |
| Aug 30, 2024 | 107 | NOTICE of Sur-Sur-Reply Expert Report of Dr. Kiran Khush, M.D., MAS Regarding the Invalidity of U.S. Patent No. 11,058,667 on behalf of Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc. by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited (Gattuso, Dominick) (Entered: 08/30/2024) (2) |
| Aug 23, 2024 | 102 | STIPULATION and [Proposed] Order Regarding Supplemental Expert Reports by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 08/23/2024) (3) |
| Aug 23, 2024 | 103 | ORAL ORDER: The discovery dispute hearing scheduled for 9/4/2024, is CANCELED. The parties have advised the dispute has been resolved. Ordered by Judge Richard G. Andrews on 8/23/2024. Associated Cases: 1:23-cv-00401-RGA, 1:20-md-02930-RGA(nms) (Entered: 08/23/2024) (0) |
| Aug 23, 2024 | 104 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 9/9/2024, at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order.. Ordered by Judge Richard G. Andrews on 8/23/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 08/23/2024) (0) |
| Aug 23, 2024 | 105 | SO ORDERED Granting Stipulation and Proposed Order Regarding Supplemental Expert Reports (D.I. 102 in 23-cv-401-RGA; D.I. 1509 in 20-md-2930-RGA). Signed by Judge Richard G. Andrews on 8/23/2024. Associated Cases: 1:20-md-02930-RGA, 1:23-cv-00401-RGA(nms) (Entered: 08/23/2024) (3) |
| Aug 19, 2024 | 101 | NOTICE to Take Deposition of Dr. Francis G. Spinale on August 22, 2024 filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 08/19/2024) (2) |
| Aug 14, 2024 | 99 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 9/4/2024, at 3:30 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 8/14/2024. Associated Cases: 1:20-md-02930-RGA, 1:23-cv-00401-RGA(nms) (Entered: 08/14/2024) (0) |
| Aug 14, 2024 | 100 | REDACTED VERSION of 96 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/14/2024 (nms). (Entered: 08/14/2024) (30) |
| Aug 7, 2024 | 98 | STIPULATION TO EXTEND TIME the deadline to submit a public, redacted version of the Letter to the Honorable Richard G. Andrews from Daniel M. Silver, Esq. on Behalf of Novartis (D.I. 1417 in C.A. No. 20-2930) to August 14, 2024 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 08/07/2024) (3) |
| Aug 1, 2024 | 97 | ORAL ORDER: The Court declines to extend the current notice requirements (see D.I. 1417 and D.I. 1418 in 20md2930-RGA). The Court is relatively certain that Novartis and MSN are all prepared to go on emergency injunctive relief. If Novartis wants to seek such relief, Novartis should file the appropriate papers by the COB August 2, 2024, and MSN can file a brief and other papers in opposition by the COB August 6, 2024, and the Court will hold a hearing on the motion(s) on August 9, 2024, at 9 a.m.. Ordered by Judge Richard G. Andrews on 8/1/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 08/01/2024) (0) |
| Jul 31, 2024 | 96 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, on behalf of Novartis regarding request for extension of the Court's June 20, 2023 Order. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Certificate of Service)(Silver, Daniel) Modified on 8/1/2024 (nms). (Entered: 07/31/2024) (0) |
| Jul 29, 2024 | 95 | Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, regarding response to Oral Order (D.I. 92 ). (Attachments: # 1 Declaration, # 2 Exhibits 1-13)(Gattuso, Dominick) Modified on 7/29/2024 (nms). (Entered: 07/29/2024) (0) |
| Jul 22, 2024 | 92 | ORAL ORDER: The redacted filing (D.I. 91 ) is REJECTED because parts of it are redacted in its entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document, or parts of it, that contains publicly available materials is prima facie evidence of bad faith. A revised redacted filing is DUE within five business days. Ordered by Judge Richard G. Andrews on 7/22/2024. (nms) (Entered: 07/22/2024) (0) |
| Jul 22, 2024 | 93 | NOTICE OF SERVICE of Reply Expert Report, filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) Modified on 7/22/2024 (nms). (Entered: 07/22/2024) (2) |
| Jul 22, 2024 | 94 | NOTICE OF SERVICE of Reply Expert Report of Dr. Francis G. Spinale on Infringement of the '667 Patent by Gerbera Therapeutics, Inc. and Nanjing Noratech Pharmaceutical Co., Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 07/22/2024) (2) |
| Jul 12, 2024 | 90 | REDACTED VERSION of 87 Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A)(Gattuso, Dominick) Modified on 7/12/2024 (nms). (Entered: 07/12/2024) (0) |
| Jul 12, 2024 | 91 | REDACTED VERSION of 86 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/12/2024 (nms). (Entered: 07/12/2024) (30) |
| Jul 5, 2024 | 89 | STIPULATION and Proposed Order to Extend Time to file public versions of D.I. 1395 and D.I. 1397 to July 12, 2024 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/8/2024 (nms). (Entered: 07/05/2024) (2) |
| Jul 3, 2024 | 88 | NOTICE OF SERVICE of Responsive Expert Report Dr. Kiran Khush, M.D., MAS Regarding Non-Infringement of U.S. Patent No. 11,058,667 on Behalf of Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc. (with Ex. A) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 07/03/2024) (2) |
| Jul 1, 2024 | 87 | [SEALED] Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, regarding discovery dispute. (Attachments: # 1 Exhibit A)(Gattuso, Dominick) Modified on 7/1/2024 (nms). (Entered: 07/01/2024) (0) |
| Jun 27, 2024 | 86 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding discovery dispute. (Attachments: # 1 Exhibits 1-13, # 2 Proposed Order, # 3 Certificate of Service)(Silver, Daniel) Modified on 6/27/2024 (nms). (Entered: 06/27/2024) (0) |
| Jun 18, 2024 | 85 | NOTICE OF SERVICE of Expert Report of Stuart D. Katz Regarding the Validity of U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/18/2024) (2) |
| Jun 12, 2024 | 84 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 7/9/2024, at 10:00 AM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 6/12/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(lah) (Entered: 06/12/2024) (0) |
| May 13, 2024 | 83 | NOTICE OF SERVICE of Opening Expert Report of Dr. Francis G. Spinale on the Infringement of the '667 Patent by Gerbera Therapeutics, Inc. and Nanjing Noratech Pharmaceutical Co., Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/13/2024) (2) |
| May 10, 2024 | 81 | NOTICE OF SERVICE of Novartis's Third Supplemental Responses and Objections to Defendant Nanjing Noratech Pharmaceutical Co., Limited's Individual Interrogatory No. 1 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/10/2024) (2) |
| May 10, 2024 | 82 | NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited's Opening Expert Report of Dr. Kiran Khush, M.D. regarding the Invalidity of U.S. Patent No. 11,058,667 filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 05/10/2024) (2) |
| May 8, 2024 | 80 | ORAL ORDER: The redactions (D.I. 1352 in 20-md-2930-RGA; D.I. 77 in 23-cv-401-RGA) as supported by the Declaration (D.I. 78 in 23-cv-401-RGA; D.I. 1353 in 20-md-2930-RGA) are APPROVED. Ordered by Judge Richard G. Andrews on 5/8/2024. Associated Cases: 1:20-md-02930-RGA, 1:23-cv-00401-RGA(nms) (Entered: 05/08/2024) (0) |
| May 7, 2024 | 79 | NOTICE OF SERVICE of Novartis's Objections and Responses to Nanjing Noratech Pharmaceutical Co., Limited's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) to Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/07/2024) (2) |
| May 6, 2024 | 77 | REDACTED VERSION of 66 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/6/2024 (nms). (Entered: 05/06/2024) (30) |
| May 6, 2024 | 78 | DECLARATION of Brian Robinson Esq. in support of 77 Redacted Document, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/6/2024 (nms). (Entered: 05/06/2024) (4) |
| May 3, 2024 | 74 | NOTICE to Take Deposition of Novartis Pharmaceuticals Corporation on May 20, 2024 @9am filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 05/03/2024) (5) |
| May 3, 2024 | 75 | NOTICE of Service of Subpoena on IQVIA Inc. by Nanjing Noratech Pharmaceutical Co., Limited (Attachments: # 1 Exhibit 1)(Gattuso, Dominick) (Entered: 05/03/2024) (0) |
| May 3, 2024 | 76 | SUBPOENA Returned Executed as to IQVIA Inc. on May 3, 2024 (Gattuso, Dominick) (Entered: 05/03/2024) (2) |
| May 1, 2024 | 73 | REDACTED VERSION of 67 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/1/2024 (nms). (Entered: 05/01/2024) (30) |
| Apr 30, 2024 | 72 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Gerbera Therapeutics Inc.. (Gattuso, Dominick) (Entered: 04/30/2024) (2) |
| Apr 29, 2024 | 71 | ORAL ORDER: The redacted filings (D.I. 1340 in 20md2930-RGA; D.I. 69 in 23cv410-RGA) are REJECTED because parts of them are redacted in entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document, or parts of it, that contains publicly available materials is prima facie evidence of bad faith. A revised redacted filing is DUE within five business days. Ordered by Judge Richard G. Andrews on 4/29/2024. Associated Cases: 1:20-md-02930-RGA, 1:23-cv-00401-RGA(nms) (Entered: 04/29/2024) (0) |
| Apr 26, 2024 | 68 | STIPULATION and [Proposed] Order Joining Gerbera Therapeutics, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 04/26/2024) (7) |
| Apr 26, 2024 | 69 | REDACTED VERSION of 66 Letter, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibits 2-14, # 3 Certificate of Service)(Gattuso, Dominick) Modified on 4/26/2024 (nms). (Entered: 04/26/2024) (0) |
| Apr 26, 2024 | 70 | SO ORDERED Granting (D.I. 180 in 22-cv-01395-RGA; D.I. 1339 in 20-md-02930-RGA; D.I. 68 in 23-cv-401-RGA) Stipulation and Proposed Order Joining Gerbera Therapeutics, Inc.. Signed by Judge Richard G. Andrews on 4/26/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 04/26/2024) (7) |
| Apr 23, 2024 | 67 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding response to Defendant Nanjing Noratech's Pharmaceutical Co.'s discovery dispute. (Attachments: # 1 Exhibit 15-16, # 2 Exhibit 17 part 1, # 3 Exhibit 17 part 2, # 4 Proposed Order, # 5 Certificate of Service)(Silver, Daniel) Modified on 4/23/2024 (nms). (Entered: 04/23/2024) (0) |
| Apr 19, 2024 | 66 | [SEALED] Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, Esq., regarding discovery dispute. (Attachments: # 1 Exhibit 1, # 2 Exhibits 2-14, # 3 Certificate of Service)(Gattuso, Dominick) Modified on 4/22/2024 (nms). (Entered: 04/19/2024) (0) |
| Apr 15, 2024 | 65 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 4/30/2024, at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 4/15/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 04/15/2024) (0) |
| Apr 5, 2024 | 63 | NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited's Amended Invalidity Contentions for U.S. Patent Nos.11,058,667 and 8,101,659 filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 04/05/2024) (2) |
| Apr 5, 2024 | 64 | NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited's First Supplemental Responses and Objections to Plaintiff's First Set Interrogatories (Nos. 1-8) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 04/05/2024) (2) |
| Apr 1, 2024 | 62 | NOTICE OF SERVICE of (i) Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Novartis Requests for Admission to Establish the Authenticity of Documents and/or Establish Documents as Business Records; (ii) Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Novartis Second Set of Interrogatories (Nos. 9-10); (iii) Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Novartis First Set of Requests For Admissions (Nos. 1-36) [HIGHLY CONFIDENTIAL-PURSUANT TO PROTECTIVE ORDER]; (iv) Noratechs Response to Novartis' First Set of Requests to Nanjing Noratech Pharmaceutical Co., Limited for the Production of Documents and Things (Nos. 1-37); and, (v) Responses and Objections to Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Nanjing Noratech Pharmaceutical Co., Limited filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 04/01/2024) (3) |
| Mar 28, 2024 | 60 | NOTICE OF SERVICE of Novartis's Second Supplemental Responses and Objections to Defendant Nanjing Noratech Pharmaceuticals Co., Limited's Individual Interrogatory No. 1 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 03/28/2024) (2) |
| Mar 28, 2024 | 61 | NOTICE OF SERVICE of Plaintiff's Second Amended Infringement Charts against Nanjing Noratech Pharmaceutical Co., Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 03/28/2024) (2) |
| Mar 27, 2024 | 59 | NOTICE OF SERVICE of Plaintiff's Supplemental Rule 26(a)(1) Initial Disclosures filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 03/27/2024) (2) |
| Mar 22, 2024 | 58 | NOTICE OF SERVICE of Novartis's Objections and Responses to Nanjing Noratech Pharmaceutical Co., Limited's Third Set of Requests for the Production of Document and Things (Nos. 24-27) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 03/22/2024) (3) |
| Mar 1, 2024 | 57 | NOTICE OF SERVICE of Novartis's First Set of Requests for Admission to Nanjing Noratech Pharmaceutical Co., Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 03/01/2024) (2) |
| Feb 29, 2024 | 55 | NOTICE OF SERVICE of (1) Novartis's First Set of Requests to Nanjing Noratech Pharmaceutical Co., Limited for the Production of Documents and Things; and (2) Novartis's Second Set of Interrogatories to Nanjing Noratech Pharmaceutical Co., Limited (Nos. 9-10) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 02/29/2024) (2) |
| Feb 29, 2024 | 56 | NOTICE OF SERVICE of (1) Novartis's Requests for Admission to Nanjing Noratech Pharmaceutical Co., Limited to Establish the Authenticity of Documents and/or Establish Documents as Business Record and (2) Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Nanjing Noratech Pharmaceutical Co., Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 02/29/2024) (3) |
| Feb 22, 2024 | 53 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding resolution of Novartis and Noratech's claim construction dispute on the 667 patent. (Silver, Daniel) Modified on 2/22/2024 (nms). (Entered: 02/22/2024) (1) |
| Feb 22, 2024 | 54 | ORAL ORDER: The request to cancel the Markman hearing set for 3/12/2024, as it related to the '667 patent (D.I. 1276 in 20-md-2930-RGA; D.I. 53 in 23-cv-401-RGA) is GRANTED. Ordered by Judge Richard G. Andrews on 2/22/2024. Associated Cases: 1:20-md-02930-RGA, 1:23-cv-00401-RGA(nms) (Entered: 02/22/2024) (0) |
| Feb 9, 2024 | 52 | NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited's Sur-Reply Claim Construction Brief with Exhibit A,filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) Modified on 2/9/2024 (nms). (Entered: 02/09/2024) (2) |
| Jan 15, 2024 | 51 | NOTICE OF SERVICE of Novartis's Reply Claim Construction Brief Regarding U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 01/15/2024) (2) |
| Dec 15, 2023 | 50 | NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited's Answering Claim Construction Brief (with Exhibits A-D) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 12/15/2023) (2) |
| Dec 11, 2023 | 49 | NOTICE OF SERVICE of Novartis's First Set of Supplemental Responses and Objections to Defendant Nanjing Noratech Pharmaceutical Co., Limited's First Set of Interrogatories (Nos. 1-2) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/11/2023) (2) |
| Dec 1, 2023 | 48 | REDACTED VERSION of 45 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 12/4/2023 (nms). (Entered: 12/01/2023) (6) |
| Nov 29, 2023 | 47 | REDACTED VERSION of 41 Letter, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibits A-J)(Gattuso, Dominick) Modified on 11/29/2023 (nms). (Entered: 11/29/2023) (0) |
| Nov 27, 2023 | 46 | STIPULATION and Order to Extend Time to file redacted version of discovery dispute letter to 12/1/2023 - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/27/2023 (nms). (Entered: 11/27/2023) (3) |
| Nov 21, 2023 | 45 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding response to Noratech's letter concerning discovery dispute. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 11/21/2023 (nms). (Entered: 11/21/2023) (0) |
| Nov 20, 2023 | 43 | NOTICE OF SERVICE of Novartis's Opening Claim Construction Brief Regarding U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/20/2023) (2) |
| Nov 17, 2023 | 41 | [SEALED] Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, Esq., regarding discovery dispute. (Attachments: # 1 Exhibits A-J, # 2 Certificate of Service)(Gattuso, Dominick) Modified on 11/20/2023 (nms). (Entered: 11/17/2023) (0) |
| Nov 17, 2023 | 42 | PROPOSED Order for 41 Letter, by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/20/2023 (nms). (Entered: 11/17/2023) (2) |
| Nov 14, 2023 | 44 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 11/30/2023 at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 11/14/2023. Associated Cases: 1:20-md-02930-RGA, 1:23-cv-00401-RGA, 1:22-cv-01395-RGA. Ordered by Judge Richard G. Andrews on 11/20/2023 (lah) (Entered: 11/20/2023) (0) |
| Oct 20, 2023 | 40 | Joint Claim Construction Chart, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-21)(Joyce, Alexandra) Modified on 10/20/2023 (nms). (Entered: 10/20/2023) (0) |
| Oct 11, 2023 | 39 | NOTICE of Appearance by Denise Seastone Kraft on behalf of Nanjing Noratech Pharmaceutical Co., Limited (Kraft, Denise) (Entered: 10/11/2023) (1) |
| Oct 9, 2023 | 38 | NOTICE OF SERVICE of Novartis's Rebuttal Proposed Construction of Claim Term and Evidence for U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 10/09/2023) (2) |
| Oct 5, 2023 | 37 | MOTION for Pro Hac Vice Appearance of Attorney Don J. Mizerk - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 10/05/2023) (4) |
| Sep 25, 2023 | 36 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Plaintiff's First Set Interrogatories (Nos. 1-8) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 09/25/2023) (2) |
| Sep 14, 2023 | 35 | MOTION for Pro Hac Vice Appearance of Attorney Thomas P. Heneghan of the law firm of Husch Blackwell LLP - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 09/14/2023) (4) |
| Sep 8, 2023 | 33 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendant Nanjing Noratech Pharmaceutical Co., Limited's First Set of Interrogatories to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 1-3) (C.A. No. 22-1395-RGA), and (2) Novartis's Responses and Objections to Defendant Nanjing Noratech Pharmaceutical Co., Limited's First Set of Interrogatories (Nos. 1-2) (C.A. No. 23-401-RGA) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/08/2023) (3) |
| Sep 8, 2023 | 34 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's Preliminary Claim Constructions and Supporting Evidence for U.S. 11,058,667 filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 09/08/2023) (2) |
| Aug 23, 2023 | 32 | NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 31 Notice of Appeal (Federal Circuit), filed by Novartis Pharmaceuticals Corporation. USCA Case Number 2023-2319. (nms) (Main Document 32 replaced on 8/23/2023) (nms). Modified on 8/23/2023 (nms). (Entered: 08/23/2023) (4) |
| Aug 17, 2023 | 30 | NOTICE OF SERVICE of Novartis's First Set of Interrogatories to Noratech (Nos. 1-8) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/17/2023) (2) |
| Aug 17, 2023 | 31 | NOTICE OF APPEAL to the Federal Circuit of 29 Judgment, . Appeal filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 08/17/2023) (2) |
| Aug 16, 2023 | 28 | PROPOSED Final Judgment Regarding U.S. Patent No. 8,101,659, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 8/16/2023 (nms). (Entered: 08/16/2023) (4) |
| Aug 16, 2023 | 29 | FINAL JUDGMENT Regarding U.S. Patent No. 8,101,659 Pursuant to Federal Rule of Civil Procedure 54(b) between Nanjing Noratech Pharmaceutical Co., Limited and Novartis Pharmaceuticals Corporation. Signed by Judge Richard G. Andrews on 8/16/2023. Associated Cases: 1:20-md-02930-RGA, 1:23-cv-00401-RGA(nms) (Entered: 08/16/2023) (4) |
| Aug 14, 2023 | 27 | MOTION for Pro Hac Vice Appearance of Attorney Deanne E. Maynard of Morrison & Forester LLP - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 08/14/2023) (4) |
| Aug 8, 2023 | 26 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's First Set of Interrogatories to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 1-2) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 08/08/2023) (2) |
| Aug 4, 2023 | 25 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's Initial Invalidity Contentions for U.S. Patent Nos.11,058,667 and 8,101,659 filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 08/04/2023) (2) |
| Jul 27, 2023 | 24 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limiteds First Set of Requests for Production of Documents and Things to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 1-17) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 07/27/2023) (2) |
| Jul 14, 2023 | 22 | NOTICE OF SERVICE of (1) Novartis's Rule 26(a) Initial Disclosures regarding the '659 and '667 Patents, (2) Novartis's Initial Paragraph 3 Disclosures Regarding Electronic Systems Information regarding the '659 and '667 Patents, and (3) Novartis's Initial Infringement Charts Against Nanjing Noratech Pharmaceutical Co., Limited regarding the '659 and '667 Patents filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 07/14/2023) (2) |
| Jul 14, 2023 | 23 | MOTION for Pro Hac Vice Appearance of Attorney Matthew M. Kamps of Husch Blackwell LLP - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 07/14/2023) (4) |
| Jul 13, 2023 | 21 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's Fed. R. Civ. P. Rule 26(a)(1)(A) and Paragraph 3 Disclosures filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 07/13/2023) (2) |
| Jul 7, 2023 | 20 | REDACTED VERSION of 16 Stipulation and Proposed Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/7/2023 (nms). (Entered: 07/07/2023) (6) |
| Jul 6, 2023 | 19 | SCHEDULING ORDER: Joinder of Parties due by 11/3/2023. Amended Pleadings due by 11/3/2023. Fact Discovery completed by 4/5/2024. Joint Claim Construction Brief due by 2/23/2024. A Markman Hearing is set for 3/12/2024, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 11/22/2024, at 9:00 AM in Courtroom 6A. A Bench Trial is set to start 12/9/2024, at 8:30 AM in Courtroom 6A (see Order for further details) Associated Cases: 1:20-md-02930-RGA, 1:23-cv-00401-RGA(nms) (Entered: 07/06/2023) (16) |
| Jul 5, 2023 | 18 | PROPOSED Scheduling Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/6/2023 (nms). (Entered: 07/05/2023) (16) |
| Jun 30, 2023 | N/A | Pro Hac Vice Attorney Melinda R. Roberts for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-md-02930-RGA et al.(mpb) (Entered: 06/30/2023) (0) |
| Jun 30, 2023 | 16 | [SEALED] STIPULATION and [Proposed] Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/30/2023 (nms). (Entered: 06/30/2023) (0) |
| Jun 30, 2023 | 17 | [SEALED] ORDER Granting (16 in 23-cv-401-RGA; 82 in 22-cv-1395-RGA; 176 in 21-cv-1330-RGA; 1091 in 20-md-2930-RGA; 95 in 22-cv-451-RGA) Stipulation and Proposed Order. Signed by Judge Richard G. Andrews on 6/30/2023.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:22-cv-00451-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 06/30/2023) (0) |
| Jun 29, 2023 | 15 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Main Document) (4) |
| Jun 29, 2023 | N/A | SO ORDERED, re (238 in 19-cv-2021-RGA; 81 in 22-cv-1395-RGA; 88 in 21-cv-1794-RGA; 644 in 19-cv-1979-RGA; 94 in 22-cv-451-RGA; 15 in 23-cv-401-RGA; 398 in 19-cv-2053-RGA; 173 in 21-cv-1330-RGA; 1088 in 20-md-2930-RGA; 88 in 21-cv-1760-RGA) MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts, filed by Novartis Pharmaceuticals Corporation. Signed by Judge Richard G. Andrews on 6/29/2023. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 06/29/2023) (0) |
| Jun 29, 2023 | 15 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Certification for Melinda R. Roberts) (1) |
| Jun 1, 2023 | 13 | ORAL ORDER: Due to a scheduling conflict the Rule 16(b) Conference set for 6/1/2023, will now commence at 4:00 PM in Courtroom 6A. Signed by Judge Richard G. Andrews on 6/1/2023. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 06/01/2023) (0) |
| Jun 1, 2023 | 14 | Amended Proposed Scheduling Order, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 6/1/2023 (nms). Modified on 6/2/2023 (nms). (Entered: 06/01/2023) (18) |
| Jun 1, 2023 | N/A | Minute Entry for proceedings held before Judge Richard G. Andrews - Rule 16(b) Conference held on 6/1/2023. Counsel for Plaintiff: D. Silver. Counsel for Defendants: D. Gattuso, D. Moore, D. Taylor, A. Ferraro, R. Weinblatt. Trial is set to begin on 12/9/2024. A Pretrial Conference is set for 11/22/2024, at 9:00 AM. A Markman hearing is set for 3/12/2024, at 9:00 AM. The parties shall submit the proposed scheduling order reflecting the rulings made at the conference. (Court Reporter Heather Triozzi.) Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(lah) (Entered: 06/01/2023) (0) |
| May 30, 2023 | 12 | PROPOSED Scheduling Order, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 5/30/2023 (nms). (Entered: 05/30/2023) (18) |
| May 10, 2023 | 11 | Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 6/1/2023, at 3:30 PM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 5/10/2023. Associated Cases: 1:23-cv-00401-RGA, 1:20-md-02930-RGA(nms) (Entered: 05/10/2023) (1) |
| May 3, 2023 | N/A | CORRECTING ENTRY: The Answer filed at D.I. 9 and Disclosure Statement filed at D.I. 10 have been removed from the docket. This case is a member to a pending MDL and therefore the filings need to reflect the MDL and civil action in all case captions. Counsel is to refile the Answer and Disclosure Statement accordingly. (nms) (Entered: 05/03/2023) (0) |
| May 3, 2023 | 9 | ANSWER to 1 Complaint with Jury Demand and Affirmative Defenses, by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) Modified on 5/3/2023 (nms). (Entered: 05/03/2023) (9) |
| May 3, 2023 | 10 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 05/03/2023) (1) |
| Apr 13, 2023 | 7 | DECLARATION of Service of Nanjing Noratech Pharmaceutical Co., Limited, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 4/13/2023 (nms). (Entered: 04/13/2023) (Main Document) (2) |
| Apr 13, 2023 | 8 | MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certifications)(Joyce, Alexandra) Modified on 4/13/2023 (nms). (Entered: 04/13/2023) (Main Document) (1) |
| Apr 13, 2023 | N/A | SO ORDERED, re 8 MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham, filed by Novartis Pharmaceuticals Corporation. Signed by Judge Richard G. Andrews on 4/13/2023. (nms) (Entered: 04/13/2023) (0) |
| Apr 13, 2023 | N/A | Pro Hac Vice Attorneys Christopher E. Loh, Jared L. Stringham for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) (Entered: 04/13/2023) (0) |
| Apr 13, 2023 | N/A | Pro Hac Vice Attorney Nicholas N. Kallas and Christina Schwarz for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 04/13/2023) (0) |
| Apr 13, 2023 | 8 | MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certifications)(Joyce, Alexandra) Modified on 4/13/2023 (nms). (Entered: 04/13/2023) (Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, a) (4) |
| Apr 13, 2023 | 7 | DECLARATION of Service of Nanjing Noratech Pharmaceutical Co., Limited, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 4/13/2023 (nms). (Entered: 04/13/2023) (Exhibit A-B) (9) |
| Apr 12, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 04/12/2023) (0) |
| Apr 11, 2023 | N/A | Remark: MDL panel has been advised. (twk) (Entered: 04/11/2023) (0) |
| Apr 10, 2023 | 1 | COMPLAINT filed against Nanjing Noratech Pharmaceutical Co., Limited ( Filing fee $ 402, receipt number ADEDC-4109426.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet)(twk) (Entered: 04/11/2023) (Main Document) (13) |
| Apr 10, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 04/11/2023) (3) |
| Apr 10, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 6, 2023 (based upon the facts currently known to Novartis). Date of Expiration of 8,101,659 Patent: January 15, 2025. Date of Expiration of 11,058,667 Patent: May 9, 2036. Thirty Month Stay Deadline: 7/14/2023. (twk) (Entered: 04/11/2023) (2) |
| Apr 10, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,101,659; 11,058,667. (twk) (Entered: 04/11/2023) (1) |
| Apr 10, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (twk) (Entered: 04/11/2023) (2) |
| Apr 10, 2023 | 6 | Summons Issued as to Nanjing Noratech Pharmaceutical Co., Limited on 4/11/2023. (twk) (Entered: 04/11/2023) (2) |
| Apr 10, 2023 | 1 | COMPLAINT filed against Nanjing Noratech Pharmaceutical Co., Limited ( Filing fee $ 402, receipt number ADEDC-4109426.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet)(twk) (Entered: 04/11/2023) (Exhibit A-B) (27) |
| Apr 10, 2023 | 1 | COMPLAINT filed against Nanjing Noratech Pharmaceutical Co., Limited ( Filing fee $ 402, receipt number ADEDC-4109426.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet)(twk) (Entered: 04/11/2023) (Civil Cover Sheet) (3) |
